As the Delhi government has rolled out global tenders for procuring Covid-19 vaccines, Delhi Chief Minster Arvind Kejriwal has expressed his apprehensions regarding the procurement process, saying that most of the vaccine manufacturers globally prefer to talk only with the Central government.
To beat variants, go big on Covaxin
SECTIONS
Last Updated: May 17, 2021, 11:07 PM IST
Share
Synopsis
Investing in upgrading a BSL-3 lab to make it fit for production will have uses beyond the manufacture of Covaxin. Going beyond the financial support it has provided, the government must step up assistance to Bharat Biotech to augment the capacity of its BSL-3 labs and vaccine manufacturing units.
Agencies
Monthly production of Covaxin is expected to go up from 20 million doses at present to 60-70 million in JulyAugust, and to 100 million in September.
With a study in the peer-reviewed journal, Clinical Infectious Diseases, revealing that indigenously developed Covaxin is effective against all known variants of Covid-19, the government should make increasing its production a chief priority. The government can raise financial assistance to Bharat Biotech, either as grant or fully paid-up orders, it can help with upgrading existing manufacturing facilities outside Bharat
Corona Hof: Neue Zahlen zu Infektionen und Impfkampagne - Lockerungen in der Stadt infranken.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infranken.de Daily Mail and Mail on Sunday newspapers.
NEW DELHI: Private hospitals have procured 80 lakh doses of anti-Covid vaccines, whereas states and UTs have bought 1.23 crore doses so far directly from vaccine manufacturers since the new vaccination policy came into effect from May 1 allowing states and the private sector to directly procure 50% of vaccines made in India.
An additional 1.27 crore doses directly procured by states and UTs is in the pipeline and will be available soon, the Centre said on Tuesday.
While lack of vaccination slots – particularly in the private sector and for those in 18-44 age group – has raised concerns during the last two weeks amid a surge in infections, the government said the supply situation will improve going forward and there will be adequate doses available for all adults.